TheEdgeResearch
Home / Stocks / NSTM

NovelStem International Corp. (NSTM)

OTC Healthcare Medical - Diagnostics & Research
$0.01 ▲ +0.00%
Market Cap
$493,325
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
2.47
52-Wk Range
0.0062-0.04
CEO
Jan H. Loeb
Country
US
Currency
USD

NovelStem International Corp. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Boca Raton, FL, US. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $493,325. On trailing twelve-month figures it carries a trailing P/E of -1.54, a net margin of 0.0%. Its beta of 2.47 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.54
Price / Sales
0.00
Price / Book
-0.24
EV / EBITDA
-18.52
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.85
Current ratio
0.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
2
IPO date
1993-11-12
Headquarters
Boca Raton, FL, US
About NovelStem International Corp.

NovelStem International Corp. concentrates its efforts on pioneering and introducing diagnostic solutions for cancer treatment, specifically with the goal of mitigating chemotherapy resistance. The company, which commenced operations in 1993, was previously recognized as Hollywood Media Corp. before adopting its current name in September of 2018. Its corporate headquarters are situated in Boca Raton, Florida.

Comparable companies

NovelStem International Corp. is most often compared with the following Healthcare names:

BICTFBMCSBMMJCHYPFDTRKEPGNFESMCGXXYISCOMJNA
More research on NSTM
NSTM technical analysis NSTM TheEdge Score Compare against peers
Open full interactive analysis & DCF →